ESPERIENZE CON FELBAMATO IN ETA PEDIATRICA

Translated title of the contribution: Clinical experience with Felbamate in paediatric age

F. Vigevano, M. R. Cilio, L. Antonini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Felbamate (FBM) is a new antiepileptic drug that has been evaluated in the Lennox-Gastaut Syndrome (LGS). When tested against placebo in an add-on, randomized, double-blind trial, FBM reduced the total seizure frequency of >50% in at least 50% of subjects. FBM appears to be well tolerated. A subsequent open-label follow-up study demonstrated that the improvement has persisted for up to 12 months. Uncontrolled studies indicate that FBM could be effective also in other pediatric epileptic syndromes.

Original languageItalian
Pages (from-to)63-66
Number of pages4
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number86-87
Publication statusPublished - 1994

Fingerprint

felbamate
Pediatrics
Anticonvulsants
Seizures
Placebos

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

ESPERIENZE CON FELBAMATO IN ETA PEDIATRICA. / Vigevano, F.; Cilio, M. R.; Antonini, L.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 86-87, 1994, p. 63-66.

Research output: Contribution to journalArticle

Vigevano, F. ; Cilio, M. R. ; Antonini, L. / ESPERIENZE CON FELBAMATO IN ETA PEDIATRICA. In: Bollettino - Lega Italiana contro l'Epilessia. 1994 ; No. 86-87. pp. 63-66.
@article{3cdb1e3afd3f4872b0131ea122a6d356,
title = "ESPERIENZE CON FELBAMATO IN ETA PEDIATRICA",
abstract = "Felbamate (FBM) is a new antiepileptic drug that has been evaluated in the Lennox-Gastaut Syndrome (LGS). When tested against placebo in an add-on, randomized, double-blind trial, FBM reduced the total seizure frequency of >50{\%} in at least 50{\%} of subjects. FBM appears to be well tolerated. A subsequent open-label follow-up study demonstrated that the improvement has persisted for up to 12 months. Uncontrolled studies indicate that FBM could be effective also in other pediatric epileptic syndromes.",
author = "F. Vigevano and Cilio, {M. R.} and L. Antonini",
year = "1994",
language = "Italian",
pages = "63--66",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "86-87",

}

TY - JOUR

T1 - ESPERIENZE CON FELBAMATO IN ETA PEDIATRICA

AU - Vigevano, F.

AU - Cilio, M. R.

AU - Antonini, L.

PY - 1994

Y1 - 1994

N2 - Felbamate (FBM) is a new antiepileptic drug that has been evaluated in the Lennox-Gastaut Syndrome (LGS). When tested against placebo in an add-on, randomized, double-blind trial, FBM reduced the total seizure frequency of >50% in at least 50% of subjects. FBM appears to be well tolerated. A subsequent open-label follow-up study demonstrated that the improvement has persisted for up to 12 months. Uncontrolled studies indicate that FBM could be effective also in other pediatric epileptic syndromes.

AB - Felbamate (FBM) is a new antiepileptic drug that has been evaluated in the Lennox-Gastaut Syndrome (LGS). When tested against placebo in an add-on, randomized, double-blind trial, FBM reduced the total seizure frequency of >50% in at least 50% of subjects. FBM appears to be well tolerated. A subsequent open-label follow-up study demonstrated that the improvement has persisted for up to 12 months. Uncontrolled studies indicate that FBM could be effective also in other pediatric epileptic syndromes.

UR - http://www.scopus.com/inward/record.url?scp=0028675772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028675772&partnerID=8YFLogxK

M3 - Articolo

SP - 63

EP - 66

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 86-87

ER -